EDIT PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

EDIT ▲ +8.44% at T+5d

SHORT call ✗ call lost -8.44% · α vs SPY -7.36% · entry $3.08 → $3.34

Next anchor: T+20d in 11d

Currently $2.50 · +18.83% from $3.08 entry (call sign-flipped)

Entry anchored
May 22, 03:59 PM ET
via Databento tick

T+1d

+15.91%

call -15.91% · α -15.90%

$3.57

settled 17d ago

T+5d

+8.44%

call -8.44% · α -7.36%

$3.34

settled 11d ago

T+20d

—

call — · α —

—

in 11d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Editas Medicine announced an underwritten public offering of common stock (or pre-funded warrants) and accompanying warrants. The size and terms are undisclosed; proceeds will go to the company. This dilutive event comes at a $270M market cap, typical for a clinical-stage biotech needing capital.

Actionable Insight

The offering will dilute existing shareholders. Monitor the prospectus supplement for exact terms (size, price, warrant coverage). Given the company's cash burn and clinical-stage status, this capital raise is expected but near-term price pressure from dilution is likely.

Key Facts

Editas Medicine commenced an underwritten public offering of common stock (or pre-funded warrants) and accompanying warrants.
All securities are being sold by the company; no selling stockholders.
Cantor and Wells Fargo Securities are joint book-running managers.
Offering size and terms are not disclosed in the press release.
The offering is being made under an effective shelf registration statement (S-3) filed in 2024 and declared effective in March 2025.
Editas Medicine is a clinical-stage gene editing company with a market cap of approximately $270M.

Financial Impact

Undisclosed amount; typical for a $270M market cap biotech, the offering could raise $50M-$100M based on sector norms, but no specific figure is provided in the filing.

dilutioncash

Risk Factors

Dilution to existing shareholders from the new shares and warrants.
Uncertainty around final offering size and pricing could amplify volatility.
Clinical-stage biotech with no approved products; capital needs may recur.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

65% bullish (20 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3300897

14 reports for EDIT

T+1T+5T+20T+60

56% Hit rate 5 of 9 directional calls best @ T+5▲ +21.01%May 26, 2026

Filters

Reports for EDIT — sortable, filterable
	Type				Now
Jun 11, 2026 1d ago	Institutional Cluster MIXED ★ 5/10	$2.49 awaiting T+5	awaiting T+5	—	$2.50 (+0.60%)
May 26, 2026 17d ago	424B5 BEARISH ★ 7/10	$3.57 $2.82	▲ +21.01%	▲ +22.22%	$2.50 (+29.97%)
May 26, 2026 17d ago	8-K BEARISH ★ 7/10	$3.57 $2.82	▲ +21.01%	▲ +22.22%	$2.50 (+29.97%)
May 26, 2026 18d ago	Press Release BEARISH ★ 8/10	$3.08 $3.34	▼ −8.44%	▼ −7.36%	$2.50 (+18.83%)
May 26, 2026 18d ago	8-K BULLISH ★ 5/10	$3.08 $3.34	▲ +8.44%	▲ +7.36%	$2.50 (−18.83%)
May 26, 2026 18d ago	424B5 BEARISH ★ 7/10	$3.08 $3.34	▼ −8.44%	▼ −7.36%	$2.50 (+18.83%)
May 26, 2026 18d ago	Press Release BEARISH ★ 6/10	$3.08 $3.34	▼ −8.44%	▼ −7.36%	$2.50 (+18.83%)
May 26, 2026 18d ago	Press Release BULLISH ★ 7/10	$3.08 $2.82	▼ −8.44%	▼ −9.65%	$2.50 (−18.83%)
May 14, 2026 4w ago	8-K BULLISH ★ 6/10	$2.85 $2.67	▼ −6.32%	▼ −5.60%	$2.50 (−12.28%)
May 14, 2026 4w ago	Press Release BULLISH ★ 5/10	$2.85 $2.67	▼ −6.32%	▼ −5.60%	$2.50 (−12.28%)

US Market Status

Market Closed — Opens Mon (46h 34m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access